Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02627573 | Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT | terminated | Phase 2 | 32 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03381118 | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | terminated | Phase 2 | 16 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations | terminated | Phase 1 / Phase 2 | 27 | Spirita Oncology, LLCINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT00655395 | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine | terminated | Phase 1 / Phase 2 | 25 | Viron Therapeutics IncINDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT02614560 | A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients | terminated | Phase 1 / Phase 2 | 14 | Seagen Inc.INDUSTRY | 1 | Jan 9, 2019 | clinicaltrials |
| NCT02730195 | Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia | terminated | Phase 2 | 9 | Emory UniversityOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT02709083 | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | terminated | Phase 2 | 7 | Emory UniversityOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00043810 | Study of Gelonin Purging of Autologous Stem Cells for Transplantation | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT02992860 | Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY(SAMBA) | terminated | Phase 2 | 25 | GWT-TUD GmbHOTHER | 2 | Oct 25, 2018 | clinicaltrials |
| NCT01866553 | Nilotinib Plus Pegylated Interferon-α2b in CML | terminated | Phase 2 | 20 | Amsterdam UMC, location VUmcOTHER | 5 | Oct 12, 2018 | clinicaltrials |
| NCT00038649 | Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C | terminated | Phase 2 | 117 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01846624 | Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 13 | David IberriOTHER | 1 | Sep 27, 2018 | clinicaltrials |
| NCT02415608 | Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis | terminated | Phase 2 | 4 | Jason Robert GotlibOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT01588951 | Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior | terminated | Phase 2 / Phase 3 | 10 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT02351037 | Study of Ibrutinib in Subjects With Acute Myeloid Leukemia | terminated | Phase 2 | 36 | Pharmacyclics LLC.INDUSTRY | 1 | Aug 14, 2018 | clinicaltrials |
| NCT01795924 | Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome(AML/MDS) | terminated | Phase 1 / Phase 2 | 13 | Biosuccess Biotech Co., Ltd.INDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | terminated | Phase 1 / Phase 2 | 10 | Everett MeyerOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02532010 | Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML(Pacritinib) | terminated | Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | terminated | Phase 2 | 5 | Emory UniversityOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | terminated | Phase 1 / Phase 2 | 8 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00593554 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | terminated | Phase 2 | 9 | Sherif S. FaragOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT01907815 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2018 | clinicaltrials |
| NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | terminated | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02198482 | Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 6 | University of UlmOTHER | 1 | Feb 28, 2018 | clinicaltrials |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00583102 | Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML | terminated | Phase 1 / Phase 2 | 23 | University of IowaOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT01442714 | Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS | terminated | Phase 2 | 33 | Stanford UniversityOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT01464359 | T-Cell Depleted Double UCB for Refractory AML | terminated | Phase 2 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00176839 | Stem Cell Transplantation for Hematological Malignancies | terminated | Phase 2 / Phase 3 | 11 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01343368 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | terminated | Phase 2 | 19 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT03108911 | Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy | terminated | Phase 2 | 1 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT02433483 | Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients | terminated | Phase 2 | 4 | St. Jude Children's Research HospitalOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT01342887 | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00673153 | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | terminated | Phase 2 | 31 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | terminated | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00863434 | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | terminated | Phase 2 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01465386 | Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission | terminated | Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01607645 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | terminated | Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | terminated | Phase 2 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01960387 | Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia(UPCI 13-066) | terminated | Phase 2 | 2 | University of PittsburghOTHER | 1 | Aug 2, 2016 | clinicaltrials |
| NCT02029417 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 25 | Akinion Pharmaceuticals ABINDUSTRY | 4 | Mar 25, 2016 | clinicaltrials |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | terminated | Phase 1 / Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 22, 2015 | clinicaltrials |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | SpirogenINDUSTRY | 1 | Nov 23, 2015 | clinicaltrials |
| NCT01794169 | Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML | terminated | Phase 2 | 130 | Karolinska University HospitalOTHER | 1 | Sep 22, 2015 | clinicaltrials |
| NCT00374296 | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | terminated | Phase 2 | 35 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Apr 5, 2019source: clinicaltrials